NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics to enable nervous system repair following trauma and disease. Its lead candidate, NVG-291, a subcutaneously administered peptide, targets mechanisms that inhibit repair and is currently in the Phase 1b/2a CONNECT SCI Study for individuals with chronic spinal cord injury, showing potential in improving function, independence, and quality of life. The company is also advancing NVG-300, a next-generation candidate in preclinical evaluation for ischemic stroke, spinal cord injury, and amyotrophic lateral sclerosis. NervGen Pharma Corp. holds a licensing agreement with Case Western Reserve University for patented technology addressing nerve damage conditions. Operating in the biotechnology sector, it addresses significant unmet needs in neurotrauma and neurologic disorders like stroke and multiple sclerosis. Founded in 2017 and headquartered in Vancouver, Canada, NervGen Pharma Corp. pursues innovative pharmacologic approaches to transform treatment paradigms for these debilitating conditions.